Abstract: A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, wherein the strain is selected from the group consisting of Prevotella copri, Prevotella stercorea, Prevotella histicola, Prevotella ruminicola, Prevotella Bryantii 25A and Prevotella distasonis. The product may be a food product.
Type:
Grant
Filed:
May 27, 2014
Date of Patent:
November 27, 2018
Assignee:
PROPREV AB
Inventors:
Inger Björck, Anne Nilsson, Fredrik Backhed, Petia Kovatcheva-Datchary
© 2024 Justia
